百克生物(688276.SH)：鼻喷流感减毒活疫苗上市许可申请获得批准

Core Viewpoint - The company, Baike Biotech (688276.SH), has received the Drug Registration Certificate for a nasal spray live attenuated influenza vaccine from the National Medical Products Administration, marking a significant advancement in its product offerings [1] Group 1: Product Development - The newly approved nasal spray influenza vaccine simulates natural infection by the influenza virus, establishing an immune barrier in the respiratory tract to prevent viral invasion [1] - This vaccine is an upgraded liquid formulation from the previously available freeze-dried version, eliminating the need for reconstitution during use, thus enhancing convenience for administration [1] - The target population for this vaccine includes individuals aged 3 to 17 years [1]